drugset
drugset / Trial / NCT07640295

Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

NCT07640295 ↗

Phase 1/2 Not yet recruiting 80 enrolled Jacobio Pharmaceuticals Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and efficacy of pan KRAS inhibitor JAB-23E73 in combination with nab-paclitaxel and gemcitabine in participants with metastatic PDAC harboring KRAS gene alterations.

Timeline

Start
2026-06-22
Primary completion
2029-12-31
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject JAB-23E73 Unknown — Oral
Background Gemcitabine Small molecule — Intravenous
Background Nab-paclitaxel Small molecule — Intravenous

Indications

pancreatic ductal adenocarcinoma